If you follow longevity content at all, you’ve heard the pitch: as we age, we accumulate senescent cells — damaged cells that refuse to die, squat in our tissues, and secrete inflammatory signals that harm their neighbors. Clear out these “zombie cells” with a senolytic compound, the story goes, and you slow aging itself. And the senolytic you can buy today, cheaply, without a prescription, is fisetin.
It’s a genuinely interesting hypothesis backed by genuinely striking animal data. It is also a textbook case of supplement marketing sprinting years ahead of human evidence — and of a dosing mismatch big enough that most people buying fisetin aren’t even taking it the way researchers do.
What fisetin actually is
Fisetin is a flavonol — a plant polyphenol in the same chemical family as quercetin. It occurs naturally in strawberries (the richest common source), apples, persimmons, onions, and cucumbers. Even so, food quantities are tiny: typical dietary intake is on the order of single-digit milligrams per day. A supplement capsule delivers a dose no realistic diet approaches, which is worth remembering whenever fisetin is described as “natural.”
For years fisetin was studied as a garden-variety antioxidant and anti-inflammatory compound, with the usual pattern: interesting cell-culture results, modest animal findings, minimal human work. What changed was the senescence research boom. In screening studies looking for compounds that selectively kill senescent cells while sparing healthy ones, fisetin performed unusually well — better than quercetin in some models.
The animal evidence, honestly stated
The animal data are the reason anyone talks about fisetin. In aged mice, intermittent high-dose fisetin has been reported to reduce markers of cellular senescence in multiple tissues and — in the most-cited work — extend both healthspan measures and remaining lifespan, even when treatment started late in life. If those results translated directly to humans, it would be among the most important findings in medicine.
Three honest caveats before extrapolating:
- Mouse lifespan interventions have a poor translation record. Plenty of compounds extend mouse lifespan; none has yet been shown to extend human lifespan. Resveratrol followed exactly this arc — spectacular early animal and cell data, followed by human trials that couldn’t confirm the excitement.
- The doses were large and intermittent. The rodent protocols used brief pulses of high-dose fisetin — the “hit and run” senolytic approach — not continuous daily supplementation.
- Senescence biology is double-edged. Senescent cells aren’t purely bad; they play roles in wound healing and tumor suppression. Indiscriminately clearing them, long-term, in healthy people is an open experiment, not an obvious win.
What human evidence exists
Human trials of fisetin as a senolytic have been running for several years now, mostly in older adults and in specific conditions where senescent-cell burden is thought to matter. The published human literature to date is best described as early: small studies, biomarker and feasibility endpoints, and safety data — not demonstrated improvements in hard outcomes like function, disease incidence, or longevity. Some trial results are still pending; nothing published so far comes close to confirming the mouse findings in people.
That’s not a knock on the research — this is how the process is supposed to work. It’s a knock on selling the conclusion before the trials read out. Our guide to reading supplement research covers this exact gap: cell and animal data generate hypotheses; only human trials test them.
The dose mismatch nobody mentions
Here’s the detail that should give every fisetin buyer pause.
The human senolytic trials generally use a protocol in the neighborhood of 20 mg/kg of body weight per day, taken on two consecutive days, repeated periodically (often monthly). For a 70 kg (155 lb) adult, that’s roughly 1,400 mg per day on dosing days — and nothing at all on the other 28 days of the month.
Now look at the supplement shelf: fisetin is mostly sold as 100-500 mg capsules with a “take one daily” label. That regimen matches neither the animal work nor the human trials. Daily low-dose fisetin is, at this point, a dosing pattern with essentially no outcome evidence of any kind behind it — it exists because daily capsules are what the supplement business knows how to sell.
If the intermittent high-dose protocol eventually proves out, daily 100 mg won’t have been it. If it doesn’t prove out, daily 100 mg definitely won’t have been it.
Bioavailability is a real problem
Like most flavonols, fisetin is poorly absorbed and rapidly metabolized. Blood levels after oral dosing are low and transient, and most circulating fisetin is conjugated into forms with uncertain activity. Various formulations (liposomal, with fats, paired with other ingredients) claim to solve this; human pharmacokinetic data for these products are sparse. Taking fisetin with a fat-containing meal is a reasonable, cost-free hedge. Paying a premium for a “high absorption” fisetin is a bet on marketing, not data.
Dosing, if you use it anyway
There is no established effective human dose — that’s the central problem. What can be said:
- Typical supplement doses: 100-500 mg/day, generally well tolerated in short-term use, unproven for any outcome.
- Trial-style senolytic dosing: ~20 mg/kg/day for two consecutive days, repeated periodically — used in supervised research settings. At these doses you are participating in an uncontrolled experiment on yourself; that’s a decision to make with a healthcare provider, not a shopping cart.
- With food: Take with a meal containing fat.
- Timeline: Since no human benefit is established, there is no timeline over which to “judge whether it’s working” — no feeling or home measurement tracks senescent-cell burden.
Safety and interactions
Short-term human studies report fisetin as generally well tolerated, with GI upset the most common complaint. The meaningful cautions:
- Blood thinners and antiplatelet drugs. Flavonols can have antiplatelet activity; combining high-dose fisetin with warfarin, DOACs, or daily aspirin deserves a conversation with your prescriber.
- Surgery. Stop at least two weeks before scheduled procedures.
- Drug metabolism. Polyphenols at supplement doses can affect drug-metabolizing enzymes and transporters; if you take narrow-therapeutic-window medications, check with a pharmacist.
- Pregnancy and nursing. Avoid. No safety data exist, and a compound selected for its ability to kill cells is a poor candidate for benefit of the doubt.
- Long-term use. Simply unstudied in humans. There is no basis for claiming multi-year daily use is safe, because nobody has looked.
Bottom line
Fisetin is a legitimate, interesting research compound with striking mouse data and an early, unfinished human evidence base. The intermittent high-dose protocol being tested in trials bears little resemblance to the daily capsules on the market, which have no outcome evidence at any dose. If longevity is your goal, the boring fundamentals — sleep, exercise, diet, and covering genuine deficiencies — still outperform every senolytic you can buy; see our longevity supplement roundup for the options that at least have human data. If you’re determined to try fisetin, keep the dose modest, take it with food, and treat every claim on the label as a hypothesis.
This article is educational and not medical advice. Talk to a healthcare provider before starting any supplement — especially if you’re pregnant, nursing, taking medication, or managing a health condition.